Gilead Sciences’ (GILD) Overweight Rating Reaffirmed at Cantor Fitzgerald

Gilead Sciences (NASDAQ:GILD)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $155.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 18.08% from the stock’s current price.

Several other equities research analysts also recently commented on GILD. Jefferies Financial Group began coverage on Gilead Sciences in a report on Tuesday, March 10th. They set a “buy” rating and a $180.00 target price for the company. Leerink Partners cut their price objective on Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Royal Bank Of Canada restated a “sector perform” rating on shares of Gilead Sciences in a report on Monday, June 8th. Daiwa Securities Group reduced their price objective on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. Finally, HSBC set a $155.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Monday. Twenty-six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $159.22.

Gilead Sciences Price Performance

GILD stock opened at $131.27 on Monday. The firm has a market cap of $162.98 billion, a PE ratio of 17.88 and a beta of 0.32. Gilead Sciences has a 12 month low of $107.75 and a 12 month high of $157.29. The firm has a 50 day simple moving average of $129.44 and a 200 day simple moving average of $134.64. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts forecast that Gilead Sciences will post -0.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the sale, the chief executive officer owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. This represents a 2.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 83,000 shares of company stock worth $10,824,500. 0.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in shares of Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after acquiring an additional 2,113,692 shares in the last quarter. State Street Corp increased its position in Gilead Sciences by 1.9% in the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock worth $7,393,921,000 after purchasing an additional 1,151,213 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Gilead Sciences by 4.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock worth $3,399,734,000 after purchasing an additional 1,195,269 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Gilead Sciences by 15.2% during the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after purchasing an additional 3,046,688 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Gilead Sciences during the 4th quarter worth about $2,617,152,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.